Department of Interventional Cardiology, Medical University of Lodz, 92-213 Lodz, Poland.
Biomolecules. 2021 Dec 4;11(12):1833. doi: 10.3390/biom11121833.
Atrial natriuretic peptide (ANP) is secreted in response to the stretching of the atrial wall. Atrial ischemia most likely impairs the ability of atrial myocytes to produce ANP. Atrial infarction (AI) is rarely diagnosed but not infrequently associated with myocardial infarction (MI). The aim of the study was to assess the association between AI and the prognostic value of N-terminal proANP (NT-proANP) in patients with MI treated with primary percutaneous coronary intervention (PCI). We evaluated data of 100 consecutive patients. Plasma levels of NT-proANP were measured by the ELISA method. ECG recordings were interpreted to diagnose AI according to Liu's criteria. All patients were followed-up prospectively for 12 months for the manifestation of major adverse cardiovascular events (MACE), defined as unplanned coronary revascularization, stroke, reinfarction or all-cause death. AI was diagnosed in 36 patients. 14% of patients developed MACE. AI did not affect the incidence of MACE or any of its components, nor the patients' prognosis. NT-proANP revealed to be a strong predictor of death but was not associated with other adverse events. Conclusions: AI in patients with MI treated with primary PCI is not connected with their prognosis nor affects the usefulness of NT-proANP in predicting death during the 12-month follow-up.
心房利钠肽（ANP）是在心房壁拉伸时分泌的。心房缺血很可能会损害心房肌细胞产生 ANP 的能力。心房梗死（AI）很少被诊断，但并不少见与心肌梗死（MI）相关。本研究旨在评估 AI 与接受经皮冠状动脉介入治疗（PCI）的 MI 患者中 N 末端 proANP（NT-proANP）的预后价值之间的关系。我们评估了 100 例连续患者的数据。通过 ELISA 法测量 NT-proANP 的血浆水平。根据刘的标准，通过心电图记录解释 AI 的诊断。所有患者均前瞻性随访 12 个月，以记录主要不良心血管事件（MACE）的表现，定义为计划外冠状动脉血运重建、中风、再梗死或全因死亡。在 36 例患者中诊断出 AI。14%的患者发生 MACE。AI 并不影响 MACE 的发生率或其任何组成部分，也不影响患者的预后。NT-proANP 被证明是死亡的强预测因子，但与其他不良事件无关。结论：在接受直接 PCI 治疗的 MI 患者中，AI 与预后无关，也不影响 NT-proANP 在预测 12 个月随访期间死亡的作用。
